Business Wire

CLARIUS-MOBILE-HEALTH

Share
Clarius Receives CE Mark Certification for Seven New Ultra-Portable Wireless Ultrasound Scanners for Apple and Android Devices

Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter and smaller, the new pocket-sized scanners that connect with Apple and Android devices are available today with revolutionary pricing and new features that will put premium handheld ultrasound into the hands of more doctors. Clarius has replaced the complex knobs and buttons found on traditional ultrasound systems with an app that uses artificial intelligence and intuitive touch-based controls. Thousands of first and second generation Clarius scanners are already in use across the continent to improve diagnostic speed and accuracy and improve procedural safety.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005072/en/

“Clinicians in Europe and the UK have been early adopters of Clarius wireless ultrasound, and we know excitement has been building for our new miniaturized Clarius HD3 because we’ve had a long list of customers eagerly waiting for CE certification,” says Clarius Founder Laurent Pelissier. “Our mission has always been to improve patient care by enabling more clinicians to use ultrasound. Now that Clarius is reduced to the size of an iPhone, easier to use, and costs less, we’re expecting more clinicians will use ultrasound to deliver the best patient care.”

In emergency environments, the Clarius C3 HD3 multipurpose scanner saves lives. Dr. Wolfgang Fleischmann, an anesthesiologist and emergency medicine physician, describes why the Red Cross chose Clarius when it sought to equip its emergency services vehicles with hospital-grade portable ultrasound.

“We had the opportunity to extensively test the Clarius scanner in our prehospital emergency environment. The product impressed us with its image quality, its reliability, its short start-up time, and good price-to-performance ratio. It prompted us to equip all our emergency doctors’ cars and ambulances with the Clarius ultrasound device.”

Clarius sets itself apart from other handheld ultrasound systems with exceptional imaging quality that rivals expensive cart-based systems, wireless connectivity, and specialty scanners with Software-as-a-Service (SaaS) designed to optimize clarity and workflows for different anatomy and applications. Clinicians can choose from seven ultrasound scanners, each designed to meet the specific requirements of a broad range of medical specialties.

With best-in-class MSK imaging, the Clarius L15 HD3 high-frequency linear scanner is a top choice amongst orthopaedic surgeons. Dr. Rudolf Berlakovits, MD, PhD, an orthopaedic surgeon in Vienna, Austria, describes the advantages of the new Clarius HD3 for safe, procedural guidance.

"To me as an orthopedic surgeon, the Clarius HD3 is a highly recommended device for interventional orthopedics and ultrasound guided orthopedic surgery. There is no cable, making it easy to keep aseptic, and the probe provides perfect handling. Another really great benefit is the possibility to share the findings with colleagues all over the world in real-time with Clarius Cloud exam management."

Clarius offers software packages designed for many specialty applications including Advanced Breast , Musculoskeletal , Obstetrics , Primary/Critical Care , Vascular , Veterinary Packages , and Aesthetics . They deliver dedicated presets, advanced workflows, comprehensive measurements, and fined tuned imaging, leveraging artificial intelligence and SaaS to deliver a complete handheld ultrasound solution that’s connected to the cloud.

Dr. Ines Verner, an Aesthetic Dermatologist based in Tel-Aviv, uses the Clarius L20 wireless ultrasound scanner to prevent complications such as vascular occlusions during aesthetic procedures like cosmetic fillers. She was among the first to try the Clarius L20 HD3 for facial aesthetics.

“It’s a breakthrough in the field. Clarius is a good fit for aesthetics because it lets me clearly see fine facial anatomy, it’s easy to use, the image quality is good, it’s wireless, and it’s small so I can take it with me from room to room,” Dr. Verner says. “Ultrasound is a gamechanger for the aesthetics industry because we can really see what we need to see instead of injecting blindly, which is what most of us used to do. Now, we can inject knowing where we’re going and not to inject where we don’t want to inject.”

New Membership Enables Ultrasound Mastery at a Lower Price

Clarius has introduced a new Clarius Membership bundle that makes the entry price lower and enables new users to fast-track ultrasound proficiency. Clarius HD3 wireless scanners now start at 2875 EUR with a 575 annual membership in Europe or 2440 GBP with 490 membership annual membership in the United Kingdom. Members gain access to all advanced SaaS, enhanced education options, and unlimited exam management in the Clarius Cloud. A three-year standard warranty is included with enhanced warranty options available through Clarius Care.

About Clarius Mobile Health

Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost. More than two million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/clariusmhealth/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release

In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new

Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release

Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye